AbbVie reports positive Phase 2 data for ABBV‑466 Crohn’s disease combo
AbbVie announced that its investigational combination of Skyrizi and trosunilimab (ABBV‑466) met its primary endpoint in a Phase 2 trial, showing higher endoscopic remission rates than either component alone. At week 12, 30.2% of patients on the combo achieved remission, rising to 40.5% by week 24, compared with 21.3% and 22.4% for Skyrizi and 18% and 20% for trosunilimab at the same time points. The safety profile showed a modest increase in serious adverse events (10.4% vs 9.6% and 9%). BMO and RBC analysts praised the results as a potential next‑generation asset for AbbVie’s inflammatory‑bowel‑disease franchise.
Why it matters
The data suggest ABBV‑466 could become a new revenue driver that extends the commercial life of Skyrizi, which may boost AbbVie’s future sales and cash generation. Analysts note the trial outcome may lift investor sentiment toward the stock, though approval still depends on later‑stage studies.
Key facts
- 1The Phase 2 study met its primary endpoint, with 30.2% of patients on ABBV‑466 achieving endoscopic remission at week 12. fool.com
- 2Remission rose to 40.5% for ABBV‑466 at week 24, versus 22.4% for Skyrizi alone and 20% for trosunilimab monotherapy. nai500.com
- 3Serious adverse event rates were 10.4% for the combination, compared with 9.6% for Skyrizi and 9% for trosunilimab. fool.com
- 4BMO Capital Markets said the early data could chart a path for a more efficacious dual‑targeting version of Skyrizi. fool.com
- 5RBC Capital Markets called the results a win for Skyrizi lifecycle management and a durable moat in inflammatory bowel disease. nai500.com
- 6AbbVie’s stock has risen nearly 30% year‑to‑date and has more than doubled over the past three years. nai500.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.